Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: How worried should we be? Journal Article

  

Authors:	Morris, P. G.; Hudis, C. A.
Article Title:	Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: How worried should we be?
Keywords:	overall survival; genetics; drug safety; side effect; treatment duration; antineoplastic agents; note; adjuvant therapy; cancer adjuvant therapy; chemotherapy, adjuvant; outcome assessment; follow up; antineoplastic agent; carboplatin; breast cancer; gene expression; heart disease; epidermal growth factor receptor 2; editorial; cyclophosphamide; drug effect; breast neoplasms; medical record review; retrospective study; risk factor; docetaxel; monoclonal antibody; antibodies, monoclonal; add on therapy; cardiovascular risk; heart death; heart failure; chemically induced disorder; adjuvant chemotherapy; cardiotoxicity; breast tumor; patient safety; receptor, erbb-2; taxane derivative; trastuzumab; anthracycline; dna topoisomerase (atp hydrolysing); heart left ventricle ejection fraction; anthracyclines; congestive heart failure; chromosome 17; ventricular function, left; heart diseases; randomized controlled trial (topic); erbb2 protein, human; phase 3 clinical trial (topic); heart left ventricle function
Journal Title:	Journal of Clinical Oncology
Volume:	28
Issue:	21
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2010-07-20
Start Page:	3407
End Page:	3410
Language:	English
DOI:	10.1200/jco.2009.26.0125
PUBMED:	20530269
PROVIDER:	scopus
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-77955296163&partnerID=40&md5=327c476ba217ce4e0eeacf08e112a742
Notes:	--- - "Cited By (since 1996): 3" - "Export Date: 20 April 2011" - "CODEN: JCOND" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/4667